ProfileGDS5678 / 1455765_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 57% 57% 55% 56% 59% 59% 57% 62% 60% 59% 56% 58% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7130662
GSM967853U87-EV human glioblastoma xenograft - Control 23.4516957
GSM967854U87-EV human glioblastoma xenograft - Control 33.4575757
GSM967855U87-EV human glioblastoma xenograft - Control 43.3231855
GSM967856U87-EV human glioblastoma xenograft - Control 53.3671256
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.620559
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6194659
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4733357
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7228562
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.597560
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5438859
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.382656
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4911958
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4510157